Autres langues Immunovant, Inc.

Actions

IMVT

US45258J1025

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 13/05/2024			Varia. 5j.	Varia. 1 janv.
29,88 ^USD	+1,67 %		+0,71 %	-29,08 %

20/04	Un initié d'Immunovant a vendu des actions d'une valeur de 990 269 $, selon un récent dépôt auprès de la SEC	MT
20/04	Un initié d'Immunovant a vendu des actions d'une valeur de 293 923 $, selon un récent dépôt auprès de la SEC	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing	20/04
Immunovant Insider Sold Shares Worth $293,923, According to a Recent SEC Filing	20/04
Immunovant Awarded U.S. Patent for IMVT-1402	12/03
Immunovant Insider Sold Shares Worth $486,362, According to a Recent SEC Filing	23/02
Immunovant Posts Narrower Fiscal Q3 Loss	12/02
Immunovant, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	12/02
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023	12/02
North American Morning Briefing : Stock Futures -2-	09/02
North American Morning Briefing : Jobs Report Tops -2-	02/02
Immunovant Insider Sold Shares Worth $383,012, According to a Recent SEC Filing	29/01
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	21/12
Immunovant Gets Positive Data From Graves' Disease Treatment Trial	20/12
Immunovant's Batoclimab for Graves' Disease Produces Meaningful Response Rates in Study; Shares Jump After Hours	20/12
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease	20/12
Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates	20/12
Top Premarket Decliners	20/12
Immunovant Insider Sold Shares Worth $490,697, According to a Recent SEC Filing	05/12
Immunovant Insider Sold Shares Worth $504,567, According to a Recent SEC Filing	05/12
Immunovant Insider Sold Shares Worth $490,668, According to a Recent SEC Filing	05/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Immunovant, Inc.

Actions

IMVT

US45258J1025

Autres langues

Filtres